

For Immediate Release

Contact: Mark Reed
Mini Mitter, a Respironics Co.
Product Manager
541-598-3832

Sandy Binder
Respironics, Inc.
MarComm Planner
724-387-4079

Actiware® Software Version 5.0 Now Available to Aid in the Collection, Archiving and Analysis of Sleep/Wake Data

Murrysville, PA, October 7, 2005 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) announces the release of Mini Mitter's Actiware® Software Version 5.0.

Version 5.0 of the Actiware Software incorporates updated features and improvements to provide sleep clinicians and researchers with an easy-to-use, secure and flexible method for the collection, archiving, and analysis of sleep/wake data. The software is also used to configure and retrieve data from Mini Mitter's Actiwatch® actigraphy products.

With the upgraded software, users can easily customize their data viewing preference and locate data on a computer hard drive. Automatic data back-ups are provided and data audit trails are maintained so changes can be easily tracked and analysis information can be recovered if needed. The software also enables users to have access to raw activity data and to properties of the data and analytical algorithms, including how data are viewed.

According to Mark Reed, product manager, Mini Mitter, "Because of the updated design and capabilities of the Actiware software, clinicians and researchers now have more options regarding how they view, process, and archive a patient's sleep/wake data. We've made a lot of these improvements because our customers specifically asked for them and the feedback we're receiving is positive."

Respironics acquired Mini Mitter in April of 2005 as part of its strategic direction to help broaden its presence beyond the core obstructive sleep apnea business.

Mini Mitter develops and markets a range of physiological monitoring products, including devices that measure sleep-wake activity, dermal and core body temperature, heart rate, and energy expenditure. The company markets these products to commercial sleep laboratories and other medical, pharmaceutical and health research institutions involved in clinical trials.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in over 125 countries and employs more than 4,000 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

#

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.